Teleflex launches new Arrow® Pressure Injectable Midline Catheter Portfolio

WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) releases their new Arrow® Pressure Injectable Midline portfolio in the US and Canada, designed to help alleviate line identification confusion. Clinicians can choose between the Arrowg+ard Blue Advance® Midline with antimicrobial and antithrombogenic protection or the traditional Arrow® Midline, both of which are available in single and double lumen options.1,2

Without quick and easy identification between midlines and PICCs, clinicians may mistakenly infuse medications through midlines that should only be infused through a central venous access device. These complications can cause disruption in patient therapy and, if serious, could lead to line replacement.

Teleflex conducted extensive research with industry-leading vascular access professionals to select the enhancements in the new Arrow® Midline Catheters. Clinician-inspired updates to the portfolio include:

• Eye catching, yellow colored catheter features and labeling to help reduce line confusion and promote patient safety
• A robust offering of 14 different kit configurations, all with pressure injection capabilities to facilitate procedural efficiency and mitigate risks
• A new Arrow® ergonomic trimmer that allows for multiple precise cuts and easy visualization
• Premium components available such as one-piece, full-body fenestrated drape, ultrasound probe cover with gel, and Tegaderm™ CHG Securement Dressing

“The Arrowg+ard Blue Advance® Midline catheter portfolio provides protection by reducing thrombus accumulation and the primary pathogens responsible for most healthcare associated infections1,2. With multiple levels of protection, critical innovations, and a streamlined workflow, it’s the perfect solution to deliver vital medications.” said Lisa Kudlacz, President and General Manager, Vascular Access Division.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

References:

1. In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
2. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus: AVAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

Rx only

Contraindication:

Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance® Midline is contraindicated in the following areas:

• Patients with known hypersensitivity to chlorhexidine
• In presence of device related infections
• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.
  

No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

Tegaderm is a registered trademark of 3M or its affiliates.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners.
© 2022 Teleflex Incorporated. All rights reserved. MC-008282

Contracts:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

John Hsu, CFA
Vice President, Investor Relations

investors.teleflex.com
610-948-2836